Apellis Pharmaceuticals, Inc.

WALTHAM, MA How do I update this listing?

Apellis Pharmaceuticals is based out of Waltham. Apellis Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Apellis Pharmaceuticals serves clients worldwide. The firm last filed a Form D notice of exempt offering of securities on 2017-08-17. The notice included securities offered of Equity

Create Alert

Contact Info

apellis pharmaceuticals, inc.
100 FIFTH AVENUE
WALTHAM MA    02451

Business Phone: 617-977-5700
SEC SIC CODE:
2834-PHARMACEUTICAL PREPARATIONS

Active Schedule 13D and 13G events

Sign in to see

Insider Transactions in the past year

Loading...

Form D Filings

Form D is a form to be used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. Form D contains basic information about the offering and the company.

Form D Filings
Filing Date Form Type Industry Group Securities Offered Total Offering Amount Total Amount Sold Total Remaining
2017-08-17 D PHARMACEUTICALS Equity 60,099,974 20,033,322 40,066,652
2016-02-08 D PHARMACEUTICALS Equity 47,135,951 47,135,951 0
2016-01-06 D PHARMACEUTICALS Equity 32,135,952 32,135,952 0
2015-06-09 D/A BIOTECHNOLOGY Equity 17,732,150 17,732,150 0
2014-12-17 D BIOTECHNOLOGY Equity 21,500,000 6,000,000 15,500,000
2014-08-27 D/A PHARMACEUTICALS Equity 24,000,000 17,842,487 6,157,513
2013-08-05 D PHARMACEUTICALS Equity 8,000,000 6,000,000 2,000,000
2012-07-25 D PHARMACEUTICALS Equity 3,000,000 692,995 2,307,005
2011-06-20 D/A PHARMACEUTICALS Equity 4,213,000 2,967,500 1,245,500
2011-06-01 D PHARMACEUTICALS Equity 4,213,000 1,688,500 2,524,500
2010-05-21 D PHARMACEUTICALS Equity 6,000,000 1,700,000 4,300,000
Other Issuers in Filings
Name Address
No Other Issuers
Related Parties included in filings
Name Address Relationship
A. SINCLAIR DUNLOP subscription required
    DIRECTOR
ALEC MACHIELS subscription required
    DIRECTOR
BIHUA CHEN subscription required
    DIRECTOR
CEDRIC FRANCOIS subscription required
    EXECUTIVE OFFICER DIRECTOR
DANIEL GEFFKEN subscription required
    EXECUTIVE OFFICER
DAVID DARST subscription required
    DIRECTOR
DAVID DARST, JR. subscription required
    DIRECTOR
DAVID WATSON subscription required
    EXECUTIVE OFFICER
DOUGLAS ONSI subscription required
    DIRECTOR
FEDERICO GROSSI subscription required
    EXECUTIVE OFFICER
GERALD CHAN subscription required
    DIRECTOR
MAHA KATABI subscription required
    DIRECTOR
MARIE-CLAUDE BERNAL subscription required
    DIRECTOR
NICOLE PERRY subscription required
    EXECUTIVE OFFICER
PASCAL DESCHATELETS subscription required
    EXECUTIVE OFFICER DIRECTOR
ROBERT ADELMAN subscription required
    DIRECTOR
ROBERT KIM subscription required
    EXECUTIVE OFFICER
SINCLAIR DUNLOP subscription required
    DIRECTOR
STEPHANIE O'BRIEN subscription required
    DIRECTOR
STEPHEN GILLIES subscription required
    DIRECTOR
STEVEN AXON subscription required
    EXECUTIVE OFFICER

Elevate your investments